The expanding roles of stereotactic body radiation therapy and oligofractionation: Toward a new practice of radiotherapy

Frontiers of Radiation Therapy and Oncology

Volumn 43, Issue , 2011, Pages 370-381

  Kavanagh, Brian D ^a   Timmerman, Robert ^b   Meyer, John L ^c  

^a Box 6510 ^*  (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Saint Francis Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; ERLOTINIB;

ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; DOSIMETRY; ESOPHAGEAL ADENOCARCINOMA; GOLD STANDARD; HUMAN; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OLIGOFRACTIONATION; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOBIOLOGY; RADIOSURGERY; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; TUMOR CELL;

DOSE FRACTIONATION; HUMANS; RADIATION ONCOLOGY; RADIOSURGERY;

ONCOLOGY;

CLINICAL APPLICATION; CLINICAL OUTCOME; CLINICAL STUDY; HYPOFRACTIONATED; RADIATION ONCOLOGY; SCIENTIFIC FOUNDATIONS; STEREOTACTIC BODY RADIATION THERAPY;

RADIOTHERAPY;

EID: 79958237192     PISSN: 00719676     EISSN: 16623789     Source Type: Book Series    
DOI: 10.1159/000322492     Document Type: Article

References (24)

1. Whelan TJ, Pignol JP, Levine MN, et al: Longterm results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-520.
2. Eriksson D, Stigbrand T: Radiation-induced cell death mechanisms. Tumour Biol 2010; 31: 363-372.
3. Ewing J: Factors determining radioresistance in tumors. Radiology 1930; 14: 186-190.
4. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-1159. (Pubitemid 36583102)
5. Yamada Y, Bilsky MH, Lovelock DM, et al: Highdose, single-fraction image-guided intensitymodulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 2008; 71: 484-490.
6. Li F, Huang Q, Chen J, et al: Apoptotic cells activate the 'phoenix rising' pathway to promote wound healing and tissue regeneration. Sci Signal 2010; 3(110):ra13.
7. Lea DE, Catcheside DG: The mechanism of the induction by radiation of chromosome aberrations in Tradescantia . J Genetics 1942; 44: 216-245.
8. Guerrero M, Li XA: Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 2004; 49: 4825-4835. (Pubitemid 39433509)
9. Curtis SB: Lethal and potentially lethal lesions induced by radiation - a unified repair model. Radiat Res 1986; 106: 252-270. (Pubitemid 16073231)
10. Park C, Papiez L, Zhang S, et al: Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 847-852. (Pubitemid 351199730)
11. Astrahan M: Some implications of linear-quadratic- linear radiation dose-response with regard to hypofractionation. Med Phys 2008; 35: 4161-4172.
12. Smith BD, Arthur DW, Buchholz TA, et al: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009; 74: 987-1001.
13. Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-1076.
14. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10.
15. Milano MT, Zhang H, Metcalfe SK, et al: Oligometastatic breast cancer treated with curativeintent stereotactic body radiation therapy. Breast Cancer Res Treat 2009; 115: 601-608.
16. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
17. Rusthoven KE, Hammerman SF, Kavanagh BD, et al: Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns- of-failure analysis. Acta Oncol 2009; 48: 578-583.
18. Madsen BL, Hsi RA, Pham HT, et al: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67: 1099-1105.
19. Katz AJ, Santoro M, Ashley R, et al: Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010; 10: 1.
20. King CR, Brooks JD, Gill H, et al: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73: 1043-1048.
21. Mahadevan A, Jain S, Goldstein M, et al: Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010; 78: 735-742.
22. Tse RV, Hawkins M, Lockwood G, et al: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664. (Pubitemid 351264363)
23. Rusthoven KE, Kavanagh BD, Cardenes H, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27: 1572-1578.
24. Rusthoven KE, Kavanagh BD, Burri SH, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009; 27: 1579-1584.